9P6E
N49P7-FR Fab in complex with BG505 MD39 SOSIP and RM20A3 Fab
This is a non-PDB format compatible entry.
Summary for 9P6E
| Entry DOI | 10.2210/pdb9p6e/pdb |
| EMDB information | 71307 |
| Descriptor | Envelope glycoprotein gp120, 2-acetamido-2-deoxy-beta-D-glucopyranose, Envelope glycoprotein gp41, ... (10 entities in total) |
| Functional Keywords | antibody engineering, hiv-1, bnab, broadly neutralizing antibody, cd4 binding site, env, viral protein |
| Biological source | Human immunodeficiency virus 1 More |
| Total number of polymer chains | 18 |
| Total formula weight | 380073.89 |
| Authors | |
| Primary citation | Kedzior, M.,Phulera, S.,Fernandez-Quintero, M.L.,Loeffler, J.R.,Joyce, C.,Woehl, J.,Abbasi, A.,Karimi, M.,Aslanabadi, A.,Hojabri, M.,Zareidoodeji, R.,Atkinson, B.,Burgos, E.F.P.,Heredia, A.,Saye-Francisco, K.,Tran, Q.,Kim, Y.,Acosta-Puente, F.,Shahin, L.,Zhou, A.,Altman, P.X.,Felbinger, N.R.,Pierce, B.G.,Sok, D.,Seaman, M.S.,Burton, D.R.,DeVico, A.L.,Ward, A.B.,Ozorowski, G.,Sajadi, M.M.,Jardine, J.G. Engineering HIV antibodies with enhanced breadth and potency of neutralization through multistate affinity maturation. Biorxiv, 2025 Cited by PubMed Abstract: Broadly neutralizing antibodies (bnAbs) against HIV hold promise as therapeutic and prophylactic agents, but realizing this potential requires antibodies that function across the antigenic heterogeneity of the HIV envelope glycoprotein (Env). Although numerous bnAbs have been isolated from infected individuals, their breadth and potency may not be sufficient to tackle global viral diversity, motivating efforts to further improve their neutralization capacity. Here, we address this challenge using a multistate antibody engineering approach integrating deep mutational scanning with combinatorial library screening across diverse Env variants. This strategy enables identification of mutation patterns that confer improved binding across antigenically distinct targets. Starting from one of the best-in-class CD4-binding site bnAbs, we performed iterative optimization to increase binding affinity across diverse Env variants. The resulting lead candidate exhibited improved breadth and up to 100-fold higher potency against pseudoviruses from large cross-clade historical and contemporary panels while maintaining biophysical and pharmacokinetic profiles conducive to clinical development. Structural and molecular dynamics analyses revealed a unique tri-tyrosine aromatic triad and reinforced electrostatic contacts that stabilized the bnAb/Env interface. These findings demonstrate that systematic engineering can generate bnAbs with enhanced breadth and potency, providing a generalizable strategy for developing therapeutic antibodies against highly diverse pathogens. PubMed: 41279620DOI: 10.1101/2025.10.22.684031 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (2.7 Å) |
Structure validation
Download full validation report
